Brian Powl - Jan 2, 2025 Form 4 Insider Report for Kura Oncology, Inc. (KURA)

Role
Chief Commercial Officer
Signature
Teresa Bair, Attorney-in-fact for Brian Powl
Stock symbol
KURA
Transactions as of
Jan 2, 2025
Transactions value $
$0
Form type
4
Date filed
1/6/2025, 04:07 PM
Previous filing
Jan 4, 2024
Next filing
Jan 28, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KURA Common Stock Award $0 +46.3K +308.33% $0.00 61.3K Jan 2, 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KURA Option to purchase common stock Award $0 +92.5K $0.00 92.5K Jan 2, 2025 Common Stock 92.5K $8.68 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Grant of Restricted Stock Units (RSUs). The RSUs vest in four equal annual installments on 1/26/26, 1/26/27, 1/26/28 and 1/26/29.
F2 This option vests in 48 equal monthly installments commencing on the grant date.